JNJ,PFE -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • The Wall Street Journal17 minutes ago

    [$$] Pfizer, Bain Capital Create New CNS Company

    and private-equity firm Bain Capital LP on Tuesday said they are forming a new company to develop drugs for disorders of the central nervous system. , which earlier this year said it would stop trying to discover new drugs for CNS disorders like Alzheimer’s disease and Parkinson’s disease, said it is contributing a portfolio of pre-commercial neuroscience assets to the new company, called Cerevel Therapeutics, LLC. Bain said funds affiliated with Bain Capital Private Equity and Bain Capital Life Sciences have committed $350 million to the new company and can provide more capital down the road if needed.

  • Bain, Pfizer launch biotech startup to tackle brain disorders
    American City Business Journals24 minutes ago

    Bain, Pfizer launch biotech startup to tackle brain disorders

    Bain Capital LP and Pfizer Inc. have teamed up to launch a new biotech in the Boston area focused on neurological disorders, including Parkinson’s and Alzheimer’s disease. The new company, called Cerevel Therapeutics LLC, is starting out with a $350 million investment from funds affiliated with Bain. In a release, Pfizer (NYSE: PFE) and Bain said that Cerevel “will be based in the Greater Boston area,” but did not specify where.

  • Investing.com49 minutes ago

    Biogen Inc Earnings, Revenue beat in Q3

    Investing.com - Biogen (NASDAQ:BIIB) Inc reported third quarter earnings that beat analyst's expectations on Tuesday and revenue that topped forecasts.

  • Investing.com52 minutes ago

    Centene Earnings miss, Revenue beats In Q3

    Investing.com - Centene reported third quarter earnings that missed analyst's expectations on Tuesday and revenue that topped forecasts.

  • Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
    Zacks55 minutes ago

    Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT

    Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.

  • A Look into Johnson & Johnson’s Diabetes Care Business
    Market Realist1 hour ago

    A Look into Johnson & Johnson’s Diabetes Care Business

    Johnson & Johnson’s (JNJ) Diabetes Care segment generated revenues of $319.0 million in the third quarter, reflecting an ~22.2% YoY (year-over-year) decline and an 11.0% decline sequentially. Johnson & Johnson’s Diabetes Care segment reported an ~20.0% YoY operational decline in the third quarter.

  • Barrons.com2 hours ago

    ASML Slumps, J&J Slips as Worries Pound the Dow

    The Dow closed in negative territory Monday, but its losses were nothing compared with Tuesday morning’s. The benchmark followed markets in China and Europe lower. Trade’s still an issue. So is Italy. And Brexit.

  • See what the IHS Markit Score report has to say about Pfizer Inc.
    Markit2 hours ago

    See what the IHS Markit Score report has to say about Pfizer Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $936 million.

  • Associated Press3 hours ago

    J&J moves to buy Japanese cosmetic products company

    NEW YORK (AP) — Johnson & Johnson is paying about $2 billion in cash for the outstanding stake of a Japanese cosmetics and skincare products company.

  • CNBC3 hours ago

    Stocks making the biggest move premarket: UTX, HOG, VZ, MMM, CAT & more

    The industrial conglomerate earned an adjusted $1.93 per share for the third quarter , 12 cents a share above forecasts. United Technologies is being helped by increased sales of aircraft parts as manufacturers push aircraft production to record levels. Harley-Davidson HOG – The motorcycle maker beat estimates by 15 cents a share , with profit of 68 cents per share.

  • TheStreet.com3 hours ago

    J&J Makes Offer to Buy Japanese Cosmetics Firm Ci:z

    Johnson & Johnson said Tuesday, Oct. 23, it was buying all the outstanding shares of Japanese cosmetics company Ci:z Holdings Co. it doesn't already own, as it tries to bolster its presence in Japan's skincare market.

  • How Johnson & Johnson’s Medical Device Business Stands Now
    Market Realist3 hours ago

    How Johnson & Johnson’s Medical Device Business Stands Now

    Johnson & Johnson’s (JNJ) Medical Devices business consists of Diabetes Care, Interventional Solutions, Orthopedics, Surgery, and Vision Care. Johnson & Johnson released its third-quarter results on October 16.

  • How Novartis’s Sandoz Performed in the Third Quarter
    Market Realist3 hours ago

    How Novartis’s Sandoz Performed in the Third Quarter

    Novartis’s (NVS) Sandoz is a market leader in differentiated generics. Sandoz reported a 6% decrease in its YoY revenues to ~$2.42 billion during the third quarter of 2018 as compared to $2.58 billion during the third quarter of 2017. The decrease includes a 4% decrease in operating revenues and a 2% negative impact of foreign exchange during the quarter.

  • The Wall Street Journal3 hours ago

    [$$] J&J to Buy Rest of Japanese Beauty Care Company

    Johnson & Johnson agreed to buy the rest of the shares in Japanese cosmetics and skin care company Ci:z Holdings in an all-cash deal valued at about 230 billion Japanese yen ($2.05 billion) that will bolster ...

  • CNBC3 hours ago

    Bain Capital teams with Pfizer to create new neuroscience-focused company

    Diseases of the central nervous system — from Alzheimer's to Parkinson's to Lou Gehrig's disease — have been incredibly difficult for drug developers to crack. Pfizer announced in January it planned to shut down early- and mid-stage neuroscience drug development, but, as it turns out, Pfizer's not walking away completely. It's teamed with investment firm Bain Capital to create a new company composed of its neuroscience assets and funded with $350 million from Bain.

  • Johnson & Johnson makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z
    Reuters5 hours ago

    Johnson & Johnson makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z

    U.S. healthcare conglomerate Johnson & Johnson said on Tuesday it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd that it does not already own for 230 billion yen in cash. ...

  • Reuters5 hours ago

    J&J makes $2.1 billion offer to buy out Japan cosmetics firm Ci:z

    By Makiko Yamazaki TOKYO (Reuters) - U.S. healthcare conglomerate Johnson & Johnson (JNJ.N) said on Tuesday it will buy all outstanding shares of Japanese skincare firm Ci:z Holdings Co Ltd (4924.T) that ...

  • PR Newswire7 hours ago

    Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.

    NEW BRUNSWICK, New Jersey, Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (4924.T) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the "tender offer") to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for ¥5,900 per share, which equates to approximately ¥230 billion. The acquisition will include the Company's range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products. The Company's skincare portfolio is expected to strengthen Johnson & Johnson's market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands.

  • PR Newswire7 hours ago

    Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.

    NEW BRUNSWICK, N.J., Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (4924.T) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the "tender offer") to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for ¥5,900 per share, which equates to approximately ¥230 billion. The acquisition will include the Company's range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products. The Company's skincare portfolio is expected to strengthen Johnson & Johnson's market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands.

  • Why Aduro Biotech Crashed 29.5% Today
    Motley Fool17 hours ago

    Why Aduro Biotech Crashed 29.5% Today

    Expectations are falling for a key drug in its pipeline.

  • Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know
    Zacks17 hours ago

    Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know

    In the latest trading session, Johnson & Johnson (JNJ) closed at $138.68, marking a -0.27% move from the previous day.

  • Pfizer (PFE) Stock Moves -0.29%: What You Should Know
    Zacks17 hours ago

    Pfizer (PFE) Stock Moves -0.29%: What You Should Know

    In the latest trading session, Pfizer (PFE) closed at $44.37, marking a -0.29% move from the previous day.

  • Pfizer: Analysts’ Recommendations on October 22
    Market Realist20 hours ago

    Pfizer: Analysts’ Recommendations on October 22

    Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.

  • Pfizer: Analysts Expect Revenue Growth in Q3
    Market Realist21 hours ago

    Pfizer: Analysts Expect Revenue Growth in Q3

    As we discussed earlier, analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to revenues of $13.2 billion during the third quarter of 2017. The revenue growth is expected to be driven by innovative health products’ strong performance.

  • Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
    Market Realist21 hours ago

    Pfizer’s Third-Quarter Earnings: Analysts’ Estimates

    Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.